De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bio-Path Holdings Beheer

Beheer criteriumcontroles 4/4

De CEO Bio-Path Holdings' is Peter Nielsen, benoemd in Jan2007, heeft een ambtstermijn van 17.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 827.12K, bestaande uit 69.5% salaris en 30.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.051% van de aandelen van het bedrijf, ter waarde $ 1.18K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 17.8 jaar en 8.4 jaar.

Belangrijke informatie

Peter Nielsen

Algemeen directeur

US$827.1k

Totale compensatie

Percentage CEO-salaris	69.5%
Dienstverband CEO	17.8yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	17.8yrs
Gemiddelde ambtstermijn bestuur	8.4yrs

Recente managementupdates

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26

Analyse CEO-vergoeding

Hoe is Peter Nielsen's beloning veranderd ten opzichte van Bio-Path Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$827k	US$575k	-US$16m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$1m	US$555k	-US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$1m	US$530k	-US$10m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$1m	US$510k	-US$11m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$735k	US$490k	-US$9m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$672k	US$490k	-US$9m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$10m
Dec 31 2017	US$594k	US$475k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 827.12K ) Peter } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Peter is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Peter Nielsen (75 yo)

17.8yrs

Tenure

US$827,117

Compensatie

Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licen...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Nielsen	Co-Founder	17.8yrs	US$827.12k	0.051% $ 1.1k
Douglas Morris	Co-Founder	17.8yrs	US$89.98k	0% $ 0
Michael Hickey	VP of Clinical Operations	1.8yrs	geen gegevens	geen gegevens
Anthony Price	Senior Vice President of Finance	no data	geen gegevens	geen gegevens
Ana Ashizawa	Senior Vice President of Research	no data	geen gegevens	geen gegevens

17.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van BPTH is doorgewinterd en ervaren (gemiddelde ambtstermijn van 17.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Nielsen	Co-Founder	16.8yrs	US$827.12k	0.051% $ 1.1k
Douglas Morris	Co-Founder	17.8yrs	US$89.98k	0% $ 0
Jorge Cortes	Chairman of the Scientific Advisory Board	9.2yrs	geen gegevens	geen gegevens
Paul Aubert	Independent Director	6.7yrs	US$73.81k	0% $ 0
Jason Fleming	Member of the Scientific Advisory Board	6.2yrs	geen gegevens	geen gegevens
Heath Cleaver	Independent Director	10.7yrs	US$85.31k	0% $ 0
D. Hooper	Member of the Scientific Advisory Board	7.7yrs	geen gegevens	geen gegevens
Aline Sherwood	Independent Director	2.6yrs	US$76.81k	0% $ 0

8.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BPTH wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).

Bio-Path Holdings Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 15, 2022

Less than half of directors are independent

Bio-Path Holdings, Inc. Appoints Aline Sherwood to its Board of Directors

Insufficient new directors

Bio-Path Holdings, Inc. Announces Resignation of Martina Molsbergen as Member of the Board and All Committees of the Board

Recent updates

Bio-Path Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders’ Equity Requirement

Bio-Path Holdings, Inc. Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors

New major risk - Financial position

Bio-Path Holdings, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings, Inc. Expands Global Patent Portfolio

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings, Inc. to Report Q4, 2023 Results on Mar 08, 2024

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $23.75 million.

New major risk - Share price stability

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $19 million.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia

No longer forecast to breakeven

Bio-Path Holdings, Inc. to Report Q3, 2023 Results on Nov 15, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target decreased by 7.7% to US$12.00

Bio-Path Holdings, Inc. to Report Q2, 2023 Results on Aug 15, 2023

New major risk - Shareholder dilution

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

New major risk - Market cap size

New minor risk - Share price stability

Bio-Path Holdings, Inc. to Report Q1, 2023 Results on May 12, 2023

Forecast to breakeven in 2025

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q3, 2022 Results on Nov 15, 2022

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path Holdings, Inc., Annual General Meeting, Dec 15, 2022

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Bio-Path Holdings, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q1, 2022 Results on May 17, 2022

Price target increased to US$12.50

Less than half of directors are independent

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc. Appoints Aline Sherwood to its Board of Directors

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings, Inc. to Report Fiscal Year 2021 Results on Mar 11, 2022

Insufficient new directors

Bio-Path Holdings, Inc. Announces Resignation of Martina Molsbergen as Member of the Board and All Committees of the Board

Bio-Path Holdings, Inc. Presents Data from Ongoing Phase 2 Study of Prexigebersen At 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$12.50

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Bio-Path Holdings, Inc. to Report Fiscal Year 2020 Results on Mar 10, 2021

New 90-day high: US$4.55

Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

Dosing underway in Bio-Path's early-stage BP1002 study

Bio-Path EPS beats by $0.07

Bio-Path Holdings, Inc. to Report Q3, 2020 Results on Nov 13, 2020